Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Trial Details

NCT ID

NCT05296564

Phase

PHASE1 / PHASE2

Sponsor

Hadassah Medical Organization

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• CYCLOPHOSPHAMIDE and FLUDARABIN
• Cyclophosphamide
• HBI 0201-ESO TCRT
• Aldesleukin

Locations (sample)

• Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

• Have histologically or cytologically confirmed diagnosis of neoplasia
• Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory/recurrent malignancy not amenable to curative treatment. Les…
• The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be avail…
• Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effect…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.